Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LbtA5
- Development stage
- Preclinical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Parenteral
01
Overview
LbtA5 is a recombinant fusion protein designed for the treatment of malignant melanoma. It consists of lebestatin (lbt), a disintegrin that specifically binds to integrin α1β1, fused to annexin V (ANV), which binds to phosphatidylserine (PS). This dual-targeting approach allows LbtA5 to specifically recognize tumor cells and tumor-associated vasculature. In preclinical studies, LbtA5 demonstrated superior anti-tumor activity compared to annexin V alone, effectively reducing the viability of melanoma cells and inhibiting tumor angiogenesis in mouse xenograft models. The fusion protein has shown efficacy comparable to dacarbazine (DTIC) in slowing tumor volume growth and inducing necrosis in melanoma tissue.
- Other names
- lebestatin-annexin Vlebestatin-annexin V fusion proteinLbt-ANV
Beyond the preview
Go deeper on LbtA5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LbtA5.